Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

124.86USD
13 Dec 2017
Change (% chg)

$-2.43 (-1.91%)
Prev Close
$127.29
Open
$126.75
Day's High
$127.61
Day's Low
$123.30
Volume
1,469,743
Avg. Vol
1,402,400
52-wk High
$147.63
52-wk Low
$35.98

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $12,516.53
Shares Outstanding(Mil.): 98.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Alnylam Completes NDA Submission To U.S. FDA For Patisiran For Treatment Of HATTR Amyloidosis

* ALNYLAM COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

Dec 12 2017

BRIEF-T. Rowe Price Associates Reports 11.7 Pct Passive Stake In Alnylam Pharmaceuticals

* T. ROWE PRICE ASSOCIATES INC REPORTS 11.7 PERCENT PASSIVE STAKE IN ALNYLAM PHARMACEUTICALS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2ALIqHV Further company coverage:

Dec 11 2017

BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran

* U.S. Food and Drug Administration (FDA) grants Alnylam breakthrough therapy designation (BTD) for Patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis with polyneuropathy

Nov 20 2017

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

Nov 16 2017

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis

Nov 16 2017

BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug

* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis

Nov 13 2017

BRIEF-Alnylam announces proposed public offering to raise about $675 mln

* Alnylam Pharmaceuticals announces proposed public offering of $675,000,000 of common stock

Nov 13 2017

BRIEF-Alnylam announces successful outcome following FDA type A meeting

* Alnylam announces successful outcome following fda type a meeting to discuss fitusiran program in hemophilia

Nov 09 2017

BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06

* Alnylam Pharmaceuticals reports third quarter 2017 financial results and highlights recent period activity

Nov 07 2017

BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran

* Alnylam initiates ENVISION Phase 3 clinical study with givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias (AHPs)

Nov 07 2017

Earnings vs. Estimates